Erasca vs. Biotech Penny Stocks

This is a news story, published by Yahoo Finance, that relates primarily to Peter Marks news.

Peter Marks news

For more Peter Marks news, you can click here:

more Peter Marks news

stocks trading & speculation news

For more stocks trading & speculation news, you can click here:

more stocks trading & speculation news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about

other biotech penny stocks

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest top biotech penny stocks news, Best Biotech Penny Stocks news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

biotech investors

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

•

Business

Business & Economics

Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Summary

Nutrition label

83% Informative

Erasca Inc. ( NASDAQ :ERAS) is a clinical-stage precision oncology company that discovers, develops, and commercializes therapies for patients with RAS /MAPK pathway-driven cancers.

Peter Marks ’ departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA .

Investors are gravitating toward companies with de-risked profiles that are less dependent on FDA flexibility.

ERAS ranks 12th on our list of the best biotech penny stocks to buy according to hedge funds.

ERAS recorded $22.5 million in in-process R&D expenses for the upfront payments associated with licensing ERAS-0015 and ERas-4001.

The company anticipates submitting IND applications to regulatory authorities in 2025 to begin clinical trials.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English